BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment.

BACKGROUND: Many patients with stage III colon adenocarcinoma do not receive adjuvant chemotherapy despite the proven survival advantage it offers.

To enhance the provision of optimal cancer care, patient characteristics associated with not receiving guideline-adherent treatment must be identified among patients with operable, stage III colon adenocarcinoma.

METHODS: This was a population-based, retrospective study of all patients who underwent surgery for stage III colon adenocarcinoma diagnosed from 2002 through 2005 in Alberta, Canada.

RESULTS: Of the 772 patients who underwent surgery for stage III colon adenocarcinoma and met the eligibility criteria, 618 patients (80%) had a consultation with an oncologist.

CONCLUSIONS: The current results indicated that the proportion of patients with stage III colon adenocarcinoma who did not receive treatment according to evidence-based guidelines was appreciable.

[MeSH-major] Adenocarcinoma / drug therapy. Chemotherapy, Adjuvant. Colonic Neoplasms / drug therapy. Guideline Adherence

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 American Cancer Society.

(PMID = 20578180.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Grant] Canada / Canadian Institutes of Health Research / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic patterns in adenocarcinoma.

The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.

A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97%), intestinal lymph node from the colon (84%), thoracic lymph node from the lung (66%), brain from the lung (64%), mediastinal lymph node from the lung (62%), supraclavicular lymph node from the breast (51%), and adrenal gland from the lung (51%).

[MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2006 American Cancer Society.

(PMID = 16518827.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers.

BACKGROUND AND AIMS: Nodal metastases are indisputable determinants of prognosis for colon and rectal cancer.

Using classical histological criteria, many attempts to predict nodal metastasis have failed, preventing the adequate management of stage I (pT1) cancer.

We investigated the role of tumour matrilysin in predicting metastatic potential, and discuss its potential use in individualising treatment of pT1 colon and rectal cancer.

METHODS: The gene signature associated with nodal metastasis was investigated by cDNA array in 24 colon and rectal cancers.

We studied 494 colon and rectal cancer patients to identify risk factors for nodal metastasis and evaluated the potential to predict nodal metastasis by either the logistic regression model or the Bayesian neural network model with built-in matrilysin.

Tumour matrilysin expression emerged as a stage independent risk factor for nodal metastasis, resulting in a similar predictive performance in receiver operating characteristic curve analysis in the two models.

CONCLUSIONS: We have provided evidence that tumour matrilysin expression is a promising biomarker predicting nodal metastasis of colon and rectal cancer.

Analysis of tumour matrilysin expression would help clinicians achieve the goal of individualised cancer treatment based on the metastatic potential of pT1 colon and rectal cancer.

[MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / enzymology. Matrix Metalloproteinase 7 / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Gastroenterol. 2000;35(3):195-200 [10755688.001]

[Cites] Proc R Soc Med. 1965 May;58:295-300 [14283879.001]

[Cites] Mol Cell Biol. 2001 Feb;21(4):1370-83 [11158322.001]

[Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61 [11526241.001]

[Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]

[Cites] Gastroenterology. 2002 Jan;122(1):60-71 [11781281.001]

[Cites] Lancet. 2002 Jan 19;359(9302):219-25 [11812558.001]

[Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]

[Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]

[Cites] J Pathol. 2003 Aug;200(5):568-76 [12898592.001]

[Cites] Clin Cancer Res. 2004 Feb 15;10(4):1401-8 [14977843.001]

[Cites] Int J Cancer. 1993 Jun 19;54(4):614-8 [8514452.001]

[Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]

[Cites] Lancet. 1995 Oct 21;346(8982):1075-9 [7564791.001]

[Cites] Br J Math Stat Psychol. 1995 Nov;48 ( Pt 2):339-58 [8527346.001]

[Cites] J Clin Epidemiol. 1996 Nov;49(11):1225-31 [8892489.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]

[Cites] Gastroenterology. 1997 Apr;112(4):1290-6 [9098015.001]

[Cites] Med Decis Making. 1998 Jan-Mar;18(1):110-21 [9456215.001]

[Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]

[Cites] Oncogene. 1999 May 6;18(18):2883-91 [10362259.001]

[Cites] Gut. 1999 Aug;45(2):252-8 [10403738.001]

[Cites] Cancer Res. 1999 Jul 15;59(14):3313-6 [10416584.001]

[Cites] Science. 1999 Oct 15;286(5439):487-91 [10521338.001]

[Cites] J Clin Oncol. 2001 Feb 1;19(3):843-50 [11157038.001]

(PMID = 16284286.001).

[ISSN] 0017-5749

[Journal-full-title] Gut

[ISO-abbreviation] Gut

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / DNA, Neoplasm; EC 3.4.24.23 / Matrix Metalloproteinase 7

[Other-IDs] NLM/ PMC1774774

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.

In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.

Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.

[MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]

[Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]

[Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]

[Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]

[Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]

[Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]

[Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]

[Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]

[Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]

[Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]

[Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]

[Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]

[Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]

[Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]

[Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]

[Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]

[Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]

[Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]

[Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]

[Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]

[Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]

[Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]

[Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]

[Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]

[Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]

[Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]

[Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]

[Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]

[Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]

[Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]

[Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]

[Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]

[Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]

[Cites] BMC Cancer. 2006;6:241 [17029629.001]

[Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]

[Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]

[Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]

[Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]

[Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]

[Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]

[Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]

[Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]

[Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]

[Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]

[Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]

(PMID = 17375048.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin

[Other-IDs] NLM/ PMC2360113

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Early stage of colonic adenocarcinoma associated with traditional serrated adenoma.

We describe a 68-year-old woman diagnosed as having a colonic adenocarcinoma associated with traditional serrated adenoma (SA) with submucosal invasion of the sigmoid colon.

Colonoscopy revealed a 0-IIa+IIc colon cancer with a SA component, about 12 mm in diameter, in the sigmoid colon.

She underwent laparoscopy-assisted resection of the sigmoid colon.

In the resected specimen, colon cancer with mucin pools was adjacent to the SA.

Cases of colonic adenocarcinoma associated with traditional SA with submucosal invasion are relatively rare.

[MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Sigmoid Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18057763.001).

[ISSN] 1349-7235

[Journal-full-title] Internal medicine (Tokyo, Japan)

[ISO-abbreviation] Intern. Med.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Galanin is up-regulated in colon adenocarcinoma.

The early diagnosis of colorectal cancer and the early detection of recurrence are central to effective treatment, as prognosis is directly related to the stage of the disease.

When colorectal cancer is diagnosed at an early, localized stage, 5-year survival is 90%.

We have implemented an approach based on the analysis of microarray data for the identification of tumor proteins that may have utility as biomarkers in colon cancer.

Expression analysis of microarray data obtained from a variety of 290 tumors and normal tissues revealed that galanin was maximally expressed in colon cancer.

These findings were corroborated by real-time quantitative PCR, in which the colon cancer cell lines LOVO, HCT15, SW480, and SW620 cell showed significantly higher levels of galanin expression than did noncolon cancer cell lines.

To evaluate galanin as a potential biomarker of colon cancer, a preliminary "training" set of serum from 40 healthy donors and 55 colon cancer patients was analyzed by ELISA.

The data pattern was confirmed by an independent set of 90 masked serum samples: 24 from healthy donors and 66 from colon cancer patients.

The galanin expression level was significantly increased with tumor size and tumor stage.

These findings justify a prospective assessment of serum galanin protein as a screening tool for colon cancer.

[MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Colonic Neoplasms / blood. Galanin / blood

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18006926.001).

[ISSN] 1055-9965

[Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 88813-36-9 / Galanin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical outcome of signet ring cell carcinoma and mucinous adenocarcinoma of the colon.

BACKGROUND: The purpose of this study was to evaluate the clinicopathologic features and prognosis of signet ring cell carcinoma (SCC) and non-SCC mucinous adenocarcinoma (MC) and to compare them with those of nonmucinous adenocarcinoma (NMC) of the colon.

The rate of spread of tumors in TNM stage IV via hematogenous routes (liver, lung, bone, and brain) was significantly lower in SCC patients (5/28, 17.9%) than in MC (40/104, 38.5%) and in NMC patients (417/694, 60.1%).

The role of resection for late stage SCC should be carefully evaluated.

[MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colonic Neoplasms / pathology

Genetic Alliance. consumer health - Signet ring cell carcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20184795.001).

[ISSN] 2309-835X

[Journal-full-title] Chang Gung medical journal

[ISO-abbreviation] Chang Gung Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] China (Republic : 1949- )

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient].

[Transliterated title] Adenocarcinoma del colon e neoplasia papillare intraduttale mucinosa multifocale sincrona del pancreas in un paziente anziano: caso clinico e revisione della letteratura.

A 78-year-old man presented with rectal bleeding which led to the diagnosis of a stenosing adenocarcinoma of the sigmoid colon.

A two-stage procedure was planned: an R0 sigmoid resection was undertaken first with an uneventful postoperative course.

[MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology. Sigmoid Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19694240.001).

[ISSN] 0009-4773

[Journal-full-title] Chirurgia italiana

[ISO-abbreviation] Chir Ital

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University].

[Transliterated title] Adenocarcinoma do pulmão: Aplicação da classificação WHO 1999/2004 à casuística do Serviço de Anatomia Patológica do Hospital da Universidade de Coimbra.

A study of 701 primary adenocarcinomas of the lung was made at the Department of Pathology of the Hospital da Universidade de Coimbra for a period of fifteen years, between 1990 and 2004.

In the same period 382 metastases were diagnosed, mainly from colon (119) and breast (66).

These conclusions were obtained via surgical specimens and when surgical biopsies were representative and those were mainly in stage IIB and IIIA.

A number of 109 cases had the final diagnosis of adenocarcinoma of the lung based on morphology and immunohistochemistry criteria.

[MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. International Classification of Diseases. Lung Neoplasms / classification. Lung Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16967175.001).

[ISSN] 0873-2159

[Journal-full-title] Revista portuguesa de pneumologia

[ISO-abbreviation] Rev Port Pneumol

[Language] por

[Publication-type] English Abstract; Journal Article

[Publication-country] Portugal

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A case of perforated small bowel adenocarcinoma as first symptom of Crohn's disease].

[Transliterated title] Adenocarcinoma perforato del piccolo intestino come prima evidente manifestazione del morbo di Crohn: case report.

A case of perforated small bowel adenocarcinoma presenting as first symptom of Crohn's disease is reported in a 53 years old male patient with abdominal pain and alteration of bowel habits.

Endoscopic bioptical sampling demonstrated a Crohn's disease in active stage.

An ileocolic resection is performed with ileo-transverse colon anastomosis.

[MeSH-major] Adenocarcinoma / complications. Crohn Disease / diagnosis. Ileal Neoplasms / complications. Intestinal Perforation / etiology

Genetic Alliance. consumer health - Crohn Disease.

MedlinePlus Health Information. consumer health - Crohn's Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16184705.001).

[ISSN] 0391-9005

[Journal-full-title] Il Giornale di chirurgia

[ISO-abbreviation] G Chir

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis].

[Transliterated title] Rezultate la distanţă după tratamentul chirurgical al adenocarcinomului colo-rectal stadiile I-III. Probleme de prognostic.

STUDY DESIGN: Prospective study on 142 consecutively cases with stage I to III colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.

The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental colon resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).

RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC stage, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated adenocarcinoma and incomplete or not performed chemotherapy.

CONCLUSION: Even with a radical surgical approach the advanced stage of colorectal adenocarcinoma has a low prognostic, but some other factors have also a high significance in postoperative outcome.

[MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18389783.001).

[ISSN] 0048-7848

[Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i

[ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi

[Language] rum

[Publication-type] English Abstract; Journal Article

[Publication-country] Romania

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome.

BACKGROUND: Patients infected with Human immunodeficiency virus (HIV) living longer with antiretroviral therapy (ART) are more likely to develop non-AIDS-defining cancers such as adenocarcinoma of the colon.

There have been limited case reports regarding HIV-associated colon adenocarcinoma.

The aim of this study was to characterize the clinicopathologic findings and outcome in a series of HIV-infected patients diagnosed and treated for colon adenocarcinoma.

PATIENTS AND METHODS: A retrospective study involving HIV-related colon adenocarcinoma was performed.

Most carcinomas (57%) involved the right colon, were largely TNM stage 4 cancers (47%), and, when present, metastases were mainly to the liver.

Immunosuppression (AIDS diagnosis and/or CD4+ < 500 cells/mm3) did not appear to correlate with tumor grade, stage, or an adverse outcome.

CONCLUSION: These data show that HIV-infected patients with adenocarcinoma of the colon tend to be young men with a high incidence of right-sided involvement.

Additional research is needed to determine if screening HIV-infected individuals for colon cancer should include younger patients and involve the entire colon.

[MeSH-major] Adenocarcinoma / complications. Colonic Neoplasms / complications. HIV Infections / complications

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19822512.001).

[ISSN] 1533-0028

[Journal-full-title] Clinical colorectal cancer

[ISO-abbreviation] Clin Colorectal Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Two-dimensional electrophoretic analysis of nuclear matrix proteins in human colon adenocarcinoma.

The aim of the present study was to observe possible qualitative and quantitative expression differences between nuclear matrix proteins (NMPs) of human colon adenocarcinoma and their mirror biopsies, using the technique of two-dimensional gel electrophoresis, in order to identify the existence of specific NMP fingerprints for colon cancer.

Colon tissues were examined ultrastructurally and NMPs were isolated biochemically, by serial extraction of lipids, soluble proteins, DNA, RNA, and intermediate filaments and were separated according to their isoelectric point (pI) and their molecular weight (MW) by high-resolution two-dimensional electrophoresis (2D).

By comparing the 2D electropherograms of colon cancer tissues and mirror biopsy tissues we observed qualitative and quantitative expression differences between their NMPs but also a differentiation of NMP composition between the stages of malignancy.

Electrophoretic results provided in this study demonstrated that the examined NMPs could be further investigated as potential markers for detection of colorectal cancer in an early stage, for the assessment of the disease progression, as well as useful tools for individual therapy and for preventing a possible recurrence of cancer and metastasis.

[MeSH-major] Adenocarcinoma / chemistry. Colonic Neoplasms / chemistry. Electrophoresis, Gel, Two-Dimensional / methods. Nuclear Matrix-Associated Proteins / analysis

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19274585.001).

[ISSN] 1521-0758

[Journal-full-title] Ultrastructural pathology

[ISO-abbreviation] Ultrastruct Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Nuclear Matrix-Associated Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Retroperitoneal margin involvement by adenocarcinoma of the caecum and ascending colon: what does it mean?

In this study, we aimed to determine the frequency of retroperitoneal margin involvement in right colon cancer and describe its relationship to tumour stage and outcome of surgical treatment.

METHOD: Two hundred and twenty-eight consecutive resections for adenocarcinoma of the ascending colon and caecum were identified between 1998 and 2006.

Tumour involvement of the posterior retroperitoneal surgical resection margin (RSRM) was recorded and correlated with tumour stage, grade and clinical outcome.

RSRM positivity was associated with advanced tumour stage and more extensive extramural spread than CRM positive rectal cancers.

CONCLUSION: Retroperitoneal surgical resection margin involvement by caecal and ascending colon carcinoma is a marker of advanced tumour stage and associated with a high incidence of synchronous and metachronous distant metastasis.

[MeSH-major] Adenocarcinoma / pathology. Cecal Neoplasms / pathology. Colonic Neoplasms / pathology. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17764533.001).

[ISSN] 1463-1318

[Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

[ISO-abbreviation] Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Three hundred and ninety- seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study.

RESULTS: The median age of the patients was 63 years (range, 21-85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer.

Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%).

Multivariate survival analysis including stage, differentiation, age, and CEA level showed that the survival for the patients with the -93AA genotype of hMLH1 was worse than for the patients with the combined -93GG and GA genotype (overall survival: hazard ratio [HR]=2.953, 95% Confidential Interval [CI], 1.273-6.850, P=0.012; disease-free survival: HR=2.299, 95% CI, 1.417-3.730, P=0.001), whereas the other polymorphisms were not associated with survival.

Accordingly, in addition to the pathologic stage, the analysis of -93G>A polymorphism of hMLH1 can help identify patient subgroups at high risk of a poor disease outcome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961540.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer?

: 4046 Background: Adjuvant chemotherapy (AC) in patients with stage III colon adenocarcinoma prevents recurrences and improves survival.

We hypothesized that AC commenced within 60 days of resection would increase survival in patients with stage II and III colon cancer.

METHODS: Patients with newly diagnosed stage II or III colon adenocarcinoma who received fluoropyrimidine based AC in two centers (a private cancer center and a large community hospital) between 2000 and 2007 were included into analysis.

116 patients (61%) were female and 35 patients (18%) had stage II disease.

The only difference between the two groups was the higher N stage in group 1.

The treating hospital and the N stage were found to be the factors affecting the OS in univariate analysis.

CONCLUSIONS: Delay of AC more than 60 days after resection is associated with inferior survival in stage II/III colon cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961564.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 4596 Background: Small bowel adenocarcinoma is a rare malignancy and is often associated with poor outcome.

METHODS: Patients aged 18-90 with adenocarcinoma of the small intestine diagnosed between 1988 and 2005 were identified from SEER data (ver. 2008).

Cox proportional hazards regression analyses were performed after adjusting for age, sex, race, T stage, grade, and primary site.

Stage I-II cases were categorized by total LN examined (1-8, 9-12, and >12).

Stage III cases were evaluated using cut-point analysis to determine the number of positive LN that predicted outcomes.

Survival among stage I/II patients (n=1,216) was dependent upon the total number of LN assessed.

5-year DSS for stage II patients was 66%, 82% (HR 0.52 95% CI .33-.84), and 88% (HR 0.38, 95% CI .23-.61) for 1-8, 9-12, >12 LN, respectively.

The optimal cutpoint of positive LN for stage III disease (n=775) was <3 compard to ≥3 with 5 year DSS of 58% vs. 37% (HR 1.49, 95% CI 1.15-1.92, P=0.002), respectively.

Among stage III patients, the LNR was even more predictive of survival than stratification by the number of positive lymph nodes as demonstrated by an improved chi-square statistic for the multivariate model (78.8 vs 63.1, P=0.0005).

CONCLUSIONS: As noted in colon cancer, the total number of LN assessed has considerable influence upon survival in stage I, II and III small bowel adenocarcinoma.

Stratifying stage III small bowel adenocarcinoma into those with <3 and ≥3 positive lymph nodes significantly improves prognostication for these patients and future staging systems should incorporate the number of positive nodes into nodal staging.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963112.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS: Archival formalin-fixed paraffin-embedded (FFPE) primary adenocarcinoma tissues obtained at initial resection with curative intent were retrieved for 145 stage I/II (pT1-4 pN0 M0) CRC pts from multiple international sites; none had neoadjuvant or adjuvant therapy.

RR by stage (I/II) = 7.00/7.28 and tumor site (colon/rectum) = 8.75/4.50.

CONCLUSIONS: A GP derived 4-gene prognostic test using FFPE tumor tissue can differentiate early stage CRC pts at high versus low risk for R within 3y better than current NCCN Guidelines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961545.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The primary tumor site was 21.9% (32) right colon, 5.5% (8) transverse colon, 45.2% (66) left colon and 27.4%(40) rectal cancer.

Adenocarcinoma was the unique histotype and mucinous differentiation was observed in 14.7% (21).

The Pathological Stage at diagnosis was Stage I 3.42% (5), II 24% (35), III 33.6% (49) and IV 39% (57).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963599.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Correlation of expression of pro-apoptotic proteins bax and bak with lymph node metastasis in colonic adenocarcinoma.

: e15042 Background: Colon cancer has been associated with disturbances in the regulation of apoptosis.

Here we investigate how these two pro-apoptotic markers correlate with lymph node (LN) metastasis in colonic adenocarcinoma (CA).

The findings suggest a role for these markers in predicting stage and patient survival in colonic adenocarcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964458.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon.

To determine the prognostic indicators that are associated with lower disease free survival (DFS) and overall survival (OS) in stage II colon cancer patients, the tumor registry records were reviewed for all patients diagnosed with stage II and III adenocarcinoma of the colon at Charleston Area Medical Center from 1986 to 1994.

The prognostic indicators of 174 stage II patients who had not undergone treatment were assessed for DFS and OS.

In addition, DFS and OS curves for stage II patients with < 7 LNR were not significantly different from survival curves for stage III patients.

Treatment decisions are made based primarily on stage, and stage II patients are not routinely offered adjuvant therapy.

[MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging. Survival Analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16422269.001).

[ISSN] 0043-3284

[Journal-full-title] The West Virginia medical journal

[ISO-abbreviation] W V Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.

However such a marker, distinctive for this particular carcinoma and allowing its detection at a sufficiently early stage of development has not yet been found.

CEA undergoes expression in all kinds of adenocarcinoma and is found both intercellularly and extracellularly.

The objective of this study has been to evaluate CD activity in the blood serum, urine and tumor tissues as well as in the colon biopsies which were not changed macroscopically and CEA concentration in the serum of colon adenocarcinoma, considering the extent of spread of cancer (TNM), the grade of the differentiation of cancer cell (G) as well as the tumor size.

The possibility of application of CD along with CEA as markers of colon adenocarcinoma has also been examined.

METHODOLOGY: The examination included the serum and urine of 21 patients as well as 12 tissues biopsies with histopathologically confirmed colon adenocarcinoma.

The reference group for the blood and urine comprised of 17 healthy controls, and for the colon adenocarcinoma tissues- samples collected from 14 people from the sites most distant from the resected tumor on the boundaries which were free of cancer cells.

RESULTS: CD activity was increased in the blood serum (p < 0.0001) and tissues (p = 0.022) of colon adenocarcinoma patients in comparison to the reference group.

CD specific activity has tendency to increase in colon adenocarcinoma tissues (p = 0.441) as compared to the reference group.

By examining data in regard to TNM clinical-histopathological classification, G and the tumor size, it could be concluded that CD activity in serum and urine in colon adenocarcinoma patients depends on progress of cancer in which CD activity increases with TNM.

A statistically significant increase in CEA concentration was found in the serum of colon adenocarcinoma patients, which was almost threefold higher than the in reference group.

CONCLUSIONS: The results of this study suggest that examination of CD activity and CEA concentration in serum, as well as CD activity in the urine, might be used in oncological diagnostics of colon adenocarcinoma.

[MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / metabolism. Carcinoembryonic Antigen / analysis. Cathepsin D / analysis. Colonic Neoplasms / chemistry. Colonic Neoplasms / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18613372.001).

[ISSN] 0172-6390

[Journal-full-title] Hepato-gastroenterology

[ISO-abbreviation] Hepatogastroenterology

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Carcinoembryonic Antigen; EC 3.4.23.5 / Cathepsin D

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Laparoscopic colectomy for colon adenocarcinoma: an 11-year retrospective review with 5-year survival rates.

BACKGROUND: Laparoscopic colectomy for the management of colon cancer remains a controversial therapeutic option, especially when the outcomes are compared with the historically accepted survival data and recurrence rates after open surgery.

The purpose of this study was to evaluate the 5-year overall and disease-free survival rates after laparoscopic colon resection for invasive colon adenocarcinoma.

METHODS: A total of 129 patients underwent consecutive laparoscopic colectomies for colon adenocarcinoma (between April 1992 and 2004 January) by a single surgeon at a single institution.

RESULTS: After patients with noninvasive disease on final pathology were excluded, the study population comprised 88 patients who underwent laparoscopic colectomies for invasive colon cancer with > 2 years of follow-up.

The Kaplan-Meier survival data were as follows for 5-year overall survival and 5-year disease-free survival, respectively stage I (n = 34) 89% and 89%; stage II (n = 22), 65% and 59%; stage III (n = 19), 72% and 67%; stages I-III combined, (n = 75), 77% and 73%.

CONCLUSIONS: For this specific cohort of patients undergoing curative laparoscopic colectomies for invasive colon adenocarcinoma, the mean follow-up was > 5 years.

Overall survival and disease-free survival for stage I, II, and III colon cancer as well as for stages I-III combined are favorable and comparable to historically acceptable open colectomy survival rates.

Overall survival and disease-free survival after laparoscopic colectomy for invasive colon cancer is no worse, and perhaps better than, the previously reported rates for the same procedure done by an open technique.

[MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Surg Endosc. 2006 Jun;20(6):996-7 [16739001.001]

[Cites] Br J Surg. 1995 Mar;82(3):295-8 [7795990.001]

[Cites] World J Surg. 1993 Jan-Feb;17(1):51-6 [8447141.001]

[Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S53-8 [8831547.001]

[Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S20-3 [8831542.001]

[Cites] Dis Colon Rectum. 1996 Feb;39(2):155-9 [8620781.001]

[Cites] J Surg Oncol. 1998 Aug;68(4):255-67 [9721713.001]

[Cites] Dis Colon Rectum. 1983 Sep;26(9):571-2 [6223795.001]

[Cites] Dis Colon Rectum. 2003 May;46(5):601-11 [12792435.001]

[Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]

[Cites] Surg Endosc. 1996 Nov;10(11):1041-4 [8881048.001]

[Cites] Ann Surg. 1992 Dec;216(6):703-7 [1466626.001]

[Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]

[Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S35-46 [8831545.001]

[Cites] Dis Colon Rectum. 1996 Feb;39(2):148-54 [8620780.001]

[Cites] Dis Colon Rectum. 1996 Feb;39(2):200-7 [8620788.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Ann Surg. 2001 Nov;234(5):590-606 [11685021.001]

[Cites] Surg Endosc. 2002 Oct;16(10):1409-12 [12140622.001]

[Cites] Surg Oncol. 2000 Nov;9(3):127-34 [11356341.001]

(PMID = 15789256.001).

[ISSN] 1432-2218

[Journal-full-title] Surgical endoscopy

[ISO-abbreviation] Surg Endosc

[Language] eng

[Publication-type] Comparative Study; Evaluation Studies; Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Resection of stage 0/I colon cancer via a circumferential periumbilical skin incision: relevance to single-incision laparoscopic surgery.

BACKGROUND: We have been performing curative resection of colon cancer via a minilaparotomy without utilizing any laparoscopic instruments as an alternative to laparoscopic-assisted approach.

Based on our experiences and improved surgical techniques, we have devised a new method for performing resection of stage 0/I colon cancer via a circumferential periumbilical skin incision that is associated with better cosmesis than standard minilaparotomy.

METHODS: The short- and long-term results of curative colectomy via a circumferential periumbilical skin incision without utilizing any laparoscopic instruments performed in selected patients with stage 0/I colon cancer between October 2003 and July 2004 were analyzed.

Pathological stage according the TNM classification was stage 0 in 4 patients and stage I in 6 patients.

CONCLUSION: Curative colectomy via a circumferential periumbilical skin incision seems oncologically safe, yields satisfactory cosmetic results, and may provide an alternative to single-incision laparoscopic surgery in selected patients with colon cancer.

[MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparotomy / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]

[Cites] Dis Colon Rectum. 2010 Apr;53(4):496-501 [20305452.001]

[Cites] Colorectal Dis. 2011 Apr;13(4):393-8 [20002691.001]

[Cites] Endoscopy. 2001 Jul;33(7):568-73 [11473326.001]

[Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]

[Cites] Surg Endosc. 2010 Sep;24(9):2321 [20177919.001]

[Cites] World J Gastroenterol. 2010 Jan 14;16(2):275-8 [20066750.001]

[Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]

[Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]

[Cites] Surg Endosc. 2010 Apr;24(4):888-90 [19760335.001]

[Cites] Eur J Surg. 1999 Jan;165(1):29-34 [10069631.001]

[Cites] Dis Colon Rectum. 2010 Mar;53(3):284-8 [20173474.001]

[Cites] Tech Coloproctol. 2010 Jun;14(2):153-9 [20428914.001]

[Cites] Dis Colon Rectum. 2009 May;52(5):1021-4 [19502875.001]

[Cites] Surg Endosc. 2005 Mar;19(3):316-20 [15624066.001]

[Cites] Colorectal Dis. 2010 Jul;12(7):698-701 [19895602.001]

[Cites] J Laparoendosc Surg. 1991 Aug;1(4):221-4 [1834273.001]

[Cites] Colorectal Dis. 2010 Jan;12(1):66-70 [19508527.001]

[Cites] Surg Endosc. 2010 Oct;24(10):2613-6 [20364353.001]

(PMID = 20730550.001).

[ISSN] 1128-045X

[Journal-full-title] Techniques in coloproctology

[ISO-abbreviation] Tech Coloproctol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.

PURPOSE: The Xeloda in Adjuvant Cancer Therapy trial, conducted in a white population of patients, established capecitabine (Xeloda) as adjuvant chemotherapy for Stage III colon cancer.

Given the ethnical difference in toxicity of adjuvant chemotherapy in colon cancer, this study was designed to evaluate the safety and efficacy of adjuvant capecitabine in Chinese patients with colon cancer.

METHODS: Chinese patients with curatively resected Stage III colon adenocarcinoma, who received adjuvant capecitabine, were entered into a prospective database.

CONCLUSIONS: A different toxicity profile of adjuvant capecitabine was noted in this study on Chinese patients with colon cancer compared with that reported in the Xeloda in Adjuvant Cancer Therapy trial, whereas the efficacy outcomes were comparable.

[MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Colonic Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives

Genetic Alliance. consumer health - Oral cancer.

Hazardous Substances Data Bank. CAPECITABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17963003.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Clinical Trial; Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] TNM staging and T-cell receptor gamma expression in colon adenocarcinoma. Correlation with disease progression?

Several studies showed the gamma-delta T-cell receptor repertoire of intestinal adenocarcinoma.

METHODS: A total of 58 patients with colon adenocarcinoma was included in the analysis.

We used the TNM staging system to grade colon cancer.

CONCLUSIONS: The results showed statistical significance between the presence of T-cell receptor gamma and N1/N2 stage lymph nodes (P = 0.001).

[MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Receptors, Antigen, T-Cell, gamma-delta / analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18705407.001).

[ISSN] 0300-8916

[Journal-full-title] Tumori

[ISO-abbreviation] Tumori

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Antigen, T-Cell, gamma-delta

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.

To study their prognostic influence in colon carcinoma, expression of APAF-1, caspase-8 and caspase-9 was determined by immunohistochemistry in normal colon mucosa (n = 8) and R0-resected stage II/III colon carcinomas (n >or= 124) using a semiquantitative score.

In normal colon, APAF-1 and caspase-8 are most strongly expressed in the luminal surface epithelium, whereas caspase-9 is expressed all along the crypt axis.

In colon carcinomas, there is considerable variability in the expression of these proapoptotic factors, although complete loss of caspase-8 and caspase-9 is rare.

The influence of caspase-8 expression was mainly seen in patients with stage III colon carcinoma (p = 0.011), whereas the prognostic influence of caspase-9 expression was significant in stage II cases (p = 0.037) and just failed to be significant in stage III tumors (p = 0.0581).

Our data suggest that, in colon carcinomas, expression of caspase-8 and caspase-9 is significantly associated with poor survival.

Caspase-9 may be an independent prognosticator in colon carcinoma.

[MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Colonic Neoplasms / metabolism

[MeSH-minor] Aged. Colon / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20013803.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces.

The American Society of Clinical Oncology and Cancer Care Ontario have recommended adjuvant chemotherapy for patients with high-risk stage II colon cancer.

We evaluated differences in concordance with guidelines in the treatment of patients with stage I-III colon cancer in the Canadian provinces of Newfoundland and Labrador and Ontario.

METHODS: We assessed clinical data and treatment from January 1999 to December 2000 for 130 patients from Newfoundland and Labrador and 315 patients from Ontario who had stage I-III colon cancer.

We evaluated factors affecting the use of chemotherapy in patients with stage II disease.

RESULTS: No patients received adjuvant therapy for stage I disease.

Forty-five of 52 patients (87%) in Newfoundland and Labrador and 108 of 115 patients (94%) in Ontario received adjuvant chemotherapy for stage III colon cancer.

Twenty of 55 patients (36%) in Newfoundland and Labrador and 44 of 116 patients (38%) in Ontario received adjuvant therapy for stage II disease.

There was a strong trend toward using chemotherapy in patients with stage II disease who were 50 years or younger, independent of high-risk status.

CONCLUSION: Concordance with CPGs for adjuvant chemotherapy in patients with stage II colon cancer was not optimal.

[MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Humans. Middle Aged. Multivariate Analysis. Newfoundland and Labrador. Ontario. Patient Selection. Registries. Risk Assessment

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] JAMA. 1999 Oct 20;282(15):1458-65 [10535437.001]

[Cites] Am J Gastroenterol. 2006 Jun;101(6):1320-8 [16771956.001]

[Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]

[Cites] Chronic Dis Can. 2000;21(2):81-6 [11007659.001]

[Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]

[Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]

[Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]

[Cites] Intern Med J. 2004 Aug;34(8):492-500 [15317548.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] CMAJ. 1993 Feb 15;148(4):507-12 [8431814.001]

[Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]

[Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]

[Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]

[Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1369-72 [7577053.001]

[Cites] Nat Med. 1995 Apr;1(4):348-52 [7585065.001]

[Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]

[Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]

[Cites] Med Care Res Rev. 2004 Dec;61(4):453-73 [15536209.001]

[Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28 [15647212.001]

[Cites] Cancer. 2005 Apr 25;105(2):101-9 [15643601.001]

[Cites] Eval Health Prof. 2006 Mar;29(1):65-88 [16510880.001]

[Cites] Qual Health Care. 1999 Sep;8(3):177-83 [10847875.001]

(PMID = 19399202.001).

[ISSN] 1488-2310

[Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie

[ISO-abbreviation] Can J Surg

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Canada

[Other-IDs] NLM/ PMC2663496

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.

In this study we detected the frequency of loss of heterozygosity (LOH) at chromosome 18q and investigated the relationship between LOH and clinicopathologic features and its prognostic value for patients with stage II colon cancer.

METHODS: A total of 106 samples of tumor tissues and corresponding normal mucosa from patients with sporadic stage-II colon cancer were included in this study.

Multivariate analysis for association between LOH and prognosis in colon cancer patients was performed with Cox proportional hazards regression model.

LOH was more frequent on the left-side, poorly-differentiated adenocarcinoma, and nonmucinous colon cancers.

The occurrence of 18q-LOH is an independent poor prognostic factor for the patients with stage-II colon cancer.

[MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 18 / genetics. Colonic Neoplasms / genetics. Loss of Heterozygosity

[MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Grading. Neoplasm Staging. Proportional Hazards Models. Survival Rate. Young Adult

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20663324.001).

[ISSN] 1000-467X

[Journal-full-title] Chinese journal of cancer

[ISO-abbreviation] Chin J Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chromogenic in situ hybridization analysis of EGFR gene copies in colon adenocarcinoma based on intra-operative imprints and tissue microarrays.

BACKGROUND: Although Epidermal Growth Factor Receptor (EGFR) over expression is a frequent event in colon adenocarcinoma (CA), identification of EGFR gene deregulation mechanisms--combined to k-ras mutations--remains the basic criterion for rational application of anti-EGFR targeted therapeutic strategies.

Significant association was established by correlating stage to chromosome 7 (p=0.024).

Furthermore, chromosome 7 aneuploidy is associated with a more advanced stage in CA.

[MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Gene Dosage. Genes, erbB-1. In Situ Hybridization / methods. Tissue Array Analysis / methods

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19795022.001).

[ISSN] 1841-8724

[Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD

[ISO-abbreviation] J Gastrointestin Liver Dis

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Romania

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of patients with high-risk stage II colon cancer for adjuvant therapy.

PURPOSE: Adjuvant therapy for Stage II colon cancer remains controversial but may be considered for patients with high-risk features.

The purpose of this study was to assess the prognostic significance of commonly reported clinicopathologic features of Stage II colon cancer to identify high-risk patients.

METHODS: We analyzed a prospectively maintained database of patients with colon cancer who underwent surgical treatment from 1990 to 2001 at a single specialty center.

We identified 448 patients with Stage II colon cancer who had been treated by curative resection alone, without postoperative chemotherapy.

Univariate and multivariate analyses identified three independent features that significantly affected disease-specific survival: tumor Stage T4 (hazard ratio (HR), 2.7; 95 percent confidence interval (CI), 1.1-6.2; P = 0.02), preoperative carcinoembryonic antigen > 5 ng/ml (HR, 2.1; 95 percent CI, 1.1-4.1; P = 0.02), and presence of lymphovascular or perineural invasion (HR, 2.1; 95 percent CI, 1-4.4; P = 0.04).

CONCLUSIONS: Patients with Stage II colon cancer generally have an excellent prognosis.

Use of commonly reported clinicopathologic features accurately stratifies Stage II colon cancer by disease-specific survival.

[MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18322753.001).

[ISSN] 1530-0358

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer.

BACKGROUND: Dukes' stage is the most important predictor of prognosis of colorectal cancer, but the association between delay of treatment (DT) and Dukes' stage is still controversial.

DT was determined through questionnaire-interviews, and Dukes' stage was obtained from medical records and pathological forms.

Dukes' stage was classified into two groups: non-advanced (Dukes' stage A or B) and advanced (Dukes' stage C or D) cancer.

Using relative risk (RR) the association between DT and stage was estimated, with short delay as the reference group.

RESULTS: The RR of advanced cancer was 1.0 (95% confidence intervals (CI): 0.8-1.3) for colon cancer patients with an intermediate DT, and 1.1 (95% CI: 0.9-1.4) for patients with a long DT.

CONCLUSION: DT was strongly associated with advanced stage of rectal cancer, but not of colon cancer.

[MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / etiology. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Female. Humans. Interviews as Topic. Male. Middle Aged. Neoplasm Staging. Practice Patterns, Physicians'. Prospective Studies. Risk Factors. Surveys and Questionnaires. Time Factors

Genetic Alliance. consumer health - Rectal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16965875.001).

[ISSN] 0361-090X

[Journal-full-title] Cancer detection and prevention

[ISO-abbreviation] Cancer Detect. Prev.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Characteristics of colorectal mucinous adenocarcinoma in Iran.

AIMS AND BACKGROUND: Mucinous adenocarcinoma (MA) colorectal cancer accounts for 10 to 15% of colorectal carcinoma.

It is generally thought that patients with MA present at a more advanced stage of disease and have a poorer prognosis than those with other types of carcinoma.

Patients evaluated on the basis of sex, age, location of tumor, stage, differentiation of tumor and family history of cancer.

Most tumors were presented in right colon.

54.3% of MA patients had advanced stage lesions.

Survival of the patients was related to disease stage (P = 0.023).

[MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21198295.001).

[ISSN] 2476-762X

[Journal-full-title] Asian Pacific journal of cancer prevention : APJCP

[ISO-abbreviation] Asian Pac. J. Cancer Prev.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Thailand

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.

We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients.

In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.

[MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Cluster Analysis. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17043639.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.

PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal colon cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.

METHODS: Forty-one patients with intraperitoneal colon cancer undergoing colectomy with curative intent were studied prospectively.

After mobilization of the colon and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.

Stage of disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).

To create a survival benefit algorithm, we assumed the following: combined fraction of Stage I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).

CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal colon cancer.

[MeSH-major] Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15690662.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.

MATERIALS AND METHODS: Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases.

[MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Mifepristone / therapeutic use

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19443374.001).

[ISSN] 0250-7005

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

[Chemical-registry-number] 320T6RNW1F / Mifepristone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis.

PURPOSE: Overexpression of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in colon adenocarcinoma (CA) is a frequent event, whereas specific deregulation mechanisms in the corresponding signaling pathways remain under investigation.

Significant associations raised correlating stage to chromosome 7 (p=0.024), HIF 1a expression to tumor anatomical location (p=0.019) and also VEGF to HIF 1a expression (p=0.001), whereas EGFR expression was not associated to EGFR gene copies.

[MeSH-major] Adenocarcinoma / chemistry. Colonic Neoplasms / chemistry. Hypoxia-Inducible Factor 1, alpha Subunit / analysis. Receptor, Epidermal Growth Factor / analysis. Signal Transduction. Tissue Array Analysis. Vascular Endothelial Growth Factor A / analysis

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20414936.001).

[ISSN] 1107-0625

[Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology

[ISO-abbreviation] J BUON

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Are 12 nodes needed to accurately stage T1 and T2 colon cancers?

Evaluation of 12 lymph nodes has been mandated to prevent colon cancer understaging.

Given that the probability of node metastases is largely associated with T-stage, are <12 nodes substandard for T1 and T2 lesions?

In SEER, 61,237 patients undergoing colon cancer resection were identified.

For each T-stage, 5-year survival rates were compared for node-negative cancers by using stepwise node cut-point comparisons (4 nodes, <4, etc.).

In conclusion, the number of nodes to stage T1 and T2 lesions may be <12.

[MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Staging / standards

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Dig Dis Sci. 2009 Apr;54(4):914-5; author reply 916 [19003528.001]

[Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]

[Cites] Colorectal Dis. 2008 Mar;10(3):231-8 [18257848.001]

[Cites] Am J Clin Pathol. 1996 Aug;106(2):209-16 [8712176.001]

[Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]

[Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]

[Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]

[Cites] J Surg Oncol. 2002 Oct;81(2):63-9 [12355405.001]

[Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]

[Cites] Arch Pathol Lab Med. 2000 Jul;124(7):958-65 [10888771.001]

[Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]

[Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]

[Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]

[Cites] Cancer. 1999 Jan 1;85(1):243-5 [9922000.001]

[Cites] Bull Am Coll Surg. 2002 Jul;87(7):13-5 [17387902.001]

[Cites] J Surg Oncol. 2008 Apr 1;97(5):383-7 [18163435.001]

[Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]

[Cites] Cancer. 1998 Apr 15;82(8):1482-6 [9554524.001]

[Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]

[Cites] Virchows Arch. 2003 Aug;443(2):133-8 [12844262.001]

[Cites] Arch Surg. 2005 Sep;140(9):881-6; discussion 886-7 [16172297.001]

[Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Dis Colon Rectum. 1999 Feb;42(2):143-54; discussion 154-8 [10211489.001]

[Cites] Scand J Gastroenterol. 2005 Jul;40(7):858-61 [16109663.001]

(PMID = 18612817.001).

[ISSN] 1573-2568

[Journal-full-title] Digestive diseases and sciences

[ISO-abbreviation] Dig. Dis. Sci.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells.

Colon adenocarcinoma is one of the most common fatal malignancies in Western countries.

The present study was conducted to assess the influence of recombinant human transforming growth factor (rhTGF)-beta1 or ACh on nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion by three human colon adenocarcinoma cell lines: HT29, LS180, and SW948, derived from different grade tumors (Duke's stage).

Colon carcinoma cells exhibited different sensitivities to rhTGF-beta1 or ACh dependent on the tumor grade and the culture model.

ACh exhibited significant inhibitory effects towards NO, endothelial nitric oxide synthase (eNOS), and IL-1beta secretion especially by tumor cells derived form Duke's C stage of colon carcinoma. rhTGF-beta1 also decreased NO, IL-1beta, and eNOS expression, but its effect was lower than that observed after the administration of ACh.

Taken together, the TGF-beta1-ACh axis may regulate colon carcinoma progression and metastasis by altering NO secretion and influence inflammatory responses by modulating IL-1beta production.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Biol Markers. 2005 Oct-Dec;20(4):235-41 [16398405.001]

[Cites] Gastroenterology. 1996 Feb;110(2):375-82 [8566583.001]

[Cites] Cell Biol Int. 2005 Jul;29(7):497-505 [15893483.001]

[Cites] World J Surg. 2005 Mar;29(3):306-11 [15711891.001]

[Cites] Cancer Metastasis Rev. 2006 Sep;25(3):387-408 [17043764.001]

[Cites] Baillieres Clin Haematol. 1992 Jul;5(3):703-21 [1333850.001]

[Cites] Med Hypotheses. 2008;70(1):43-51 [17587508.001]

[Cites] Clin Immunol. 2002 Feb;102(2):169-78 [11846459.001]

[Cites] Biochem Pharmacol. 2004 Jun 15;67(12):2197-205 [15163551.001]

[Cites] Cancer Res. 2003 Oct 15;63(20):6744-50 [14583469.001]

[Cites] J Am Coll Cardiol. 1997 Feb;29(2):308-17 [9014982.001]

[Cites] Br J Cancer. 1996 Dec;74(12):1955-60 [8980396.001]

[Cites] Eur J Cancer. 2000 Jun;36(10):1288-91 [10882868.001]

[Cites] Lancet Oncol. 2001 Mar;2(3):149-56 [11902565.001]

[Cites] Clin Exp Metastasis. 1997 Nov;15(6):557-67 [9344040.001]

[Cites] Dig Dis Sci. 1999 May;44(5):916-21 [10235597.001]

[Cites] J Cancer Res Clin Oncol. 2003 May;129(5):272-8 [12748850.001]

[Cites] Int J Mol Med. 2002 Jun;9(6):651-7 [12011984.001]

[Cites] Eur J Cancer. 2001 Jan;37(2):224-33 [11166150.001]

[Cites] Ann Med. 1995 Jun;27(3):359-67 [7546626.001]

[Cites] Mutat Res. 2004 Nov 2;555(1-2):107-19 [15476855.001]

[Cites] Drug Resist Updat. 2006 Jun;9(3):157-73 [16822706.001]

[Cites] Clin Exp Metastasis. 2005;22(4):341-9 [16170670.001]

[Cites] Gastroenterology. 1995 Aug;109(2):483-9 [7615197.001]

[Cites] Med Hypotheses. 2007;69(6):1272-6 [17553629.001]

[Cites] Cancer Immunol Immunother. 2004 Aug;53(8):723-8 [15034673.001]

[Cites] Inflamm Res. 2004 Feb;53(2):60-5 [15021970.001]

[Cites] Life Sci. 2003 Mar 28;72(18-19):2159-68 [12628474.001]

[Cites] J Transl Med. 2006 Nov 10;4:48 [17096856.001]

(PMID = 19551451.001).

[ISSN] 1543-706X

[Journal-full-title] In vitro cellular & developmental biology. Animal

[ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Interleukin-1beta; 0 / Transforming Growth Factor beta1; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type III; N9YNS0M02X / Acetylcholine

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnostic and prognostic microRNAs in stage II colon cancer.

Here, we used microarrays to profile the expression of 315 human miRNAs in 10 normal mucosa samples and 49 stage II colon cancers differing with regard to microsatellite status and recurrence of disease.

We successfully verified the expression of selected miRNAs using real-time reverse transcription-PCR assays for mature miRNAs, whereas in situ hybridization was used to detect the accumulation of miR-145 and miR-320 in normal epithelial cells and adenocarcinoma cells.

Functional studies showed that miR-145 potently suppressed growth of three different colon carcinoma cell lines.

In conclusion, our results suggest that perturbed expression of numerous miRNAs in colon cancer may have a functional effect on tumor cell behavior, and, furthermore, that some miRNAs with prognostic potential could be of clinical importance.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Gastroenterology. 2009 Mar;136(3):1112-4; discussion 1114 [19167396.001]

(PMID = 18676867.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN498 microRNA, human; 0 / MicroRNAs

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer.

The tumor samples were extracted from formalin-fixed paraffin-embedded primary tissues derived from patients with Stage II CRC who developed disease recurrence within two years (n=10), or were disease-free for at least 4 years (n=12).

This suggests that the expression ratio of Map7/B2M may serve as a valuable prognostic marker in patients with Stage II colon cancer, and potentially guide therapeutic decision making.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Genes Dev. 2000 Jun 1;14(11):1332-42 [10837026.001]

[Cites] Int J Colorectal Dis. 2007 Aug;22(8):887-95 [17235506.001]

[Cites] CA Cancer J Clin. 1999 Jul-Aug;49(4):202-19 [11198882.001]

[Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]

[Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]

[Cites] Gynecol Oncol. 2004 Feb;92(2):719-25 [14766275.001]

[Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]

[Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]

[Cites] J Immunol. 1989 Jan 1;142(1):352-8 [2462591.001]

[Cites] J Exp Med. 1989 Jan 1;169(1):309-14 [2642530.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] Cancer Res. 1992 Mar 1;52(5):1201-4 [1737380.001]

[Cites] J Cell Biol. 1995 Nov;131(4):1015-24 [7490279.001]

[Cites] Tumori. 1997 Jan-Feb;83(1 Suppl):S39-41 [9154066.001]

[Cites] Inflamm Bowel Dis. 1998 Aug;4(3):196-202 [9741021.001]

[Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]

[Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]

[Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2080-7 [16609019.001]

[Cites] Clin Cancer Res. 2007 May 15;13(10):2849-54 [17504982.001]

[Cites] CA Cancer J Clin. 2007 May-Jun;57(3):168-85 [17507442.001]

[Cites] Biotechniques. 2000 Sep;29(3):548-50, 552-4, 556 passim [10997270.001]

(PMID = 18695889.001).

[ISSN] 1019-6439

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / K23 CA093419; United States / NCI NIH HHS / CA / R21 CA097875; United States / NCI NIH HHS / CA / R33 CA097875; United States / NCI NIH HHS / CA / CA097875

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microtubule-Associated Proteins; 0 / beta 2-Microglobulin

[Other-IDs] NLM/ NIHMS388523; NLM/ PMC3399116

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.

Two recent North American studies have shown that completion of 5-fluorouracil (5FU)-based adjuvant chemotherapy is a major prognostic factor for the survival of elderly stage III colon cancer patients.

The study cohort comprised 851 stage III colon cancer patients treated by surgery alone and 461 who initiated the Mayo chemotherapy regime.

The current and previous studies demonstrate the importance of completing adjuvant 5-FU-based chemotherapy for colon cancer.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]

[Cites] J Clin Oncol. 2002 Mar 15;20(6):1491-8 [11896096.001]

[Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]

[Cites] Br J Cancer. 2003 May 19;88(10):1510-5 [12771914.001]

[Cites] Br J Cancer. 2003 Jun 16;88(12):1859-65 [12799627.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]

[Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]

[Cites] J Clin Oncol. 2003 Oct 15;21(20):3729-36 [14551292.001]

[Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5 [14676107.001]

[Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]

[Cites] Oncology (Williston Park). 2004 May;18(6):751-5; discussion 755-8 [15214594.001]

[Cites] Eur J Cancer. 2004 Oct;40(15):2230-6 [15454247.001]

[Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] J Clin Oncol. 1992 Jul;10(7):1171-5 [1607921.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]

[Cites] J Clin Oncol. 1994 Jun;12(6):1291-5 [8201391.001]

[Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]

[Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]

[Cites] Eur J Cancer. 1998 Nov;34(12):1871-5 [10023308.001]

[Cites] Cancer. 2005 Mar 15;103(6):1165-71 [15693031.001]

[Cites] J Clin Oncol. 2005 Mar 20;23(9):1819-25 [15774775.001]

[Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]

[Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]

[Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]

[Cites] Dig Surg. 2005;22(6):401-14 [16479107.001]

[Cites] J Natl Cancer Inst. 2006 May 3;98(9):610-9 [16670386.001]

[Cites] J Clin Oncol. 2006 May 20;24(15):2368-75 [16618946.001]

[Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]

[Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]

[Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]

[Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]

(PMID = 17299387.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

[Other-IDs] NLM/ PMC2360063

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor.

PURPOSE: Colon obstruction is suggested to be a predictor of poor outcome in colon cancer.

However, the effect of obstruction on outcome in patients with different tumor-nodes-metastases (TNM) stage cancer has not been fully addressed.

The aim of this study is to determine whether colon obstruction predicts surgical and long-term oncologic outcomes in patients with proximal colon cancer.

METHODS: A total of 1,492 consecutive patients underwent open resection of primary adenocarcinoma of right colon in a single institution between January 1995 and December 2005.

Univariate and multivariate analyses were performed to identify colon obstruction and other predictors of surgical and oncologic outcomes.

RESULTS: Among 1,492 patients, 306 (20.5%) patients presented with colon obstruction.

Obstruction predicted a worse long-term disease-free survival (DFS) among patients with stage II-III disease (log-rank test, p = 0.0003).

The data were stratified by TNM stage.

Obstruction predicted a worse DFS among patients with TNM stage II cancer (598 patients; log-rank test, p = 0.001; Cox regression, p = 0.012), but it was not a predictor in TNM stage III cancer patients (424 patients; p = 0.116; p = 0.108).

CONCLUSIONS: Colon obstruction was an independent predictor of long-term outcome only in TNM stage II but not in stage III proximal colon cancer.

Patients with TNM stage II obstructive colon cancer could be included in future trials of adjuvant therapies.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Surgery. 2000 Apr;127(4):370-6 [10776426.001]

[Cites] Int J Colorectal Dis. 2009 Jun;24(6):665-76 [19238405.001]

[Cites] Am J Surg. 2004 Apr;187(4):497-500 [15041498.001]

[Cites] Eur J Cancer. 1996 Feb;32A(2):295-302 [8664045.001]

[Cites] Colorectal Dis. 2008 Jan;10(1):33-40 [17672872.001]

[Cites] Ann Surg. 1983 Dec;198(6):743-52 [6357118.001]

[Cites] Hepatogastroenterology. 2008 Jul-Aug;55(85):1288-92 [18795674.001]

[Cites] Br J Surg. 1989 Sep;76(9):965-9 [2804601.001]

[Cites] Br J Surg. 1986 Aug;73(8):663-70 [3742184.001]

[Cites] Rev Med Chil. 2004 Jun;132(6):691-700 [15332370.001]

[Cites] Ann Surg Oncol. 2006 Jun;13(6):887-98 [16614880.001]

[Cites] J Surg Oncol. 1991 Jul;47(3):188-92 [2072703.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]

[Cites] Am J Clin Pathol. 2003 Jan;119(1):108-13 [12520705.001]

[Cites] Br J Surg. 2006 Apr;93(4):483-8 [16555262.001]

[Cites] Lancet. 1986 Oct 18;2(8512):904-7 [2876336.001]

[Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]

[Cites] Br Med J. 1979 Sep 1;2(6189):515-7 [497669.001]

[Cites] Br J Surg. 1985 Apr;72(4):296-302 [3986481.001]

[Cites] Dis Colon Rectum. 1991 Sep;34(9):759-62 [1914740.001]

[Cites] Dis Colon Rectum. 1997 Mar;40(3):326-31 [9118749.001]

(PMID = 20135321.001).

[ISSN] 1432-1262

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Clinical features of colorectal mucinous adenocarcinoma].

OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma (NMAC).

METHODS: Clinical data of 2089 cases with colorectal cancer from 1994 to 2007 in our hospital, including 169 patients diagnosed as mucinous adenocarcinoma were analyzed retrospectively.

The rates of tumor location in colon (97 cases,57.4% vs 814 cases, 44.3%, in MAC and NMAC) were significantly different (P<0.01).

The rate of radical resection (86.4% vs 91.5%), hepatic metastasis (5.3% vs 8.5%) and local recurrence had no significant difference between patients with mucinous and non-mucinous adenocarcinoma (P>0.05).

In comparison to NMAC patients, MAC patients were worse in long-term overall survival, the survival of receiving radical resection and of TNM stage (II+III) group (P<0.01).

Survivals were not significantly different in TNM stage I and IV groups between mucinous and non-mucinous adenocarcinoma (P>0.05).

CONCLUSIONS: Colorectal mucinous adenocarcinoma patients have worse outcome in comparison to non-mucinous adenocarcinoma patients.

Mucinous adenocarcinoma may have special biological behavior, which is an independent prognostic factor for patients with colorectal cancer.

[MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19742341.001).

[ISSN] 1671-0274

[Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

[ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease.

Examination of the colon was normal.

The biopsy of the ileal mass was consistent with an adenocarcinoma arising from the terminal ileum.

Findings were consistent with ileal adenocarcinoma in the setting of Crohn's disease.

The pathology was stage 1 adenocarcinoma.

This is a unique case in that on a screening colonoscopy, a favorable ileal adenocarcinoma was discovered in the setting of asymptomatic, undiagnosed ileal Crohn's disease in a patient whose father had Crohn's disease diagnosed postmortem.

[MeSH-major] Adenocarcinoma / diagnosis. Crohn Disease / diagnosis. Ileal Neoplasms / diagnosis

Genetic Alliance. consumer health - Crohn Disease.

MedlinePlus Health Information. consumer health - Crohn's Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]

[Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]

[Cites] J Clin Gastroenterol. 1984 Jun;6(3):217-24 [6327804.001]

[Cites] World J Surg. 1985 Dec;9(6):914-20 [4082613.001]

[Cites] Cancer. 1989 Jan 15;63(2):360-3 [2910443.001]

[Cites] Surg Gynecol Obstet. 1991 Nov;173(5):343-9 [1948581.001]

[Cites] Dig Dis Sci. 1992 Aug;37(8):1179-84 [1499440.001]

[Cites] Gastroenterology. 1992 Nov;103(5):1444-51 [1358741.001]

[Cites] J Gastroenterol Hepatol. 1999 Nov;14(11):1132-4 [10574144.001]

[Cites] Clin Imaging. 1999 Sep-Oct;23(5):298-301 [10665347.001]

[Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]

[Cites] Scand J Gastroenterol. 2001 Jun;36(6):641-6 [11424324.001]

[Cites] Eur J Gastroenterol Hepatol. 2002 Jul;14(7):805-10 [12169995.001]

[Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]

[Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]

[Cites] Australas Radiol. 2003 Dec;47(4):450-2 [14641202.001]

[Cites] Endoscopy. 2003 Dec;35(12):1009-14 [14648412.001]

[Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):106-16 [14716243.001]

[Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93 [14984375.001]

[Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]

[Cites] Dis Colon Rectum. 2004 May;47(5):778-81 [15037927.001]

[Cites] Radiographics. 2004 May-Jun;24(3):689-702 [15143222.001]

[Cites] Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S32-4 [15168828.001]

[Cites] Clin Gastroenterol Hepatol. 2004 Jun;2(6):491-7 [15181618.001]

[Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]

[Cites] World J Gastroenterol. 2004 Sep 1;10(17):2585-7 [15300912.001]

[Cites] Gastroenterol Nurs. 2004 Jul-Aug;27(4):170-5 [15326402.001]

[Cites] Lancet. 1973 Jan 6;1(7793):24-6 [4118541.001]

[Cites] Gut. 1973 Feb;14(2):120-4 [4696534.001]

[Cites] Am J Dig Dis. 1973 Dec;18(12):1095-8 [4761532.001]

[Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]

[Cites] Cancer. 1976 Jun;37(6):2948-59 [949714.001]

[Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]

[Cites] Gut. 1982 Mar;23(3):188-93 [7040175.001]

[Cites] Dis Colon Rectum. 1993 Jul;36(7):654-61 [8348849.001]

[Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]

[Cites] Med Clin North Am. 1994 Nov;78(6):1399-412 [7967916.001]

[Cites] Gut. 1994 Nov;35(11):1507-8 [7828962.001]

[Cites] Am J Gastroenterol. 1996 Mar;91(3):434-40 [8633487.001]

[Cites] Dis Colon Rectum. 1996 Nov;39(11):1315-21 [8918446.001]

[Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]

[Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]

[Cites] Am J Surg Pathol. 1998 Mar;22(3):275-84 [9500769.001]

[Cites] Eur J Gastroenterol Hepatol. 1998 May;10(5):431-2 [9619392.001]

[Cites] Surgery. 1956 Feb;39(2):347-51 [13298987.001]

[Cites] Gastroenterology. 2006 Apr;130(4):1039-46 [16618397.001]

[Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5 [12950413.001]

(PMID = 18698685.001).

[ISSN] 1007-9327

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] China

[Other-IDs] NLM/ PMC2738795

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.

PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in Stage III colon cancer are useful as prognostic factors.

METHODS: Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.

CONCLUSIONS: In Stage III colon cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.

[MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

Genetic Alliance. consumer health - Metastatic cancer.

Hazardous Substances Data Bank. MITOMYCIN C .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16625329.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Overexpression of DARPP-32 in colorectal adenocarcinoma.

Our aim is to investigate the expression of DARPP-32 protein in colorectal adenocarcinoma.

The expression of DARPP-32 in colorectal adenocarcinoma tissues 33/42, 78.57% was higher than that in normal colon epithelial tissues (31/60, 51.67%, p <0.05).

There was no significant relationship between the expression of DARPP-32 and the differentiation, metastasis and Dukes' stage of colorectal adenocarcinoma (p >0.05).

Both DARPP-32 and its truncated isoform t-DARPP were overexpressed in colorectal adenocarcinoma (t=2.306, p=0.028), while t-DARPP was more frequently detected.

[MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Nerve Tissue Proteins / metabolism. Phosphoproteins / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15707466.001).

[ISSN] 1368-5031

[Journal-full-title] International journal of clinical practice

[ISO-abbreviation] Int. J. Clin. Pract.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Dopamine and cAMP-Regulated Phosphoprotein 32; 0 / Nerve Tissue Proteins; 0 / Phosphoproteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Transforming growth factor-beta1 modulates metalloproteinase-2 and -9, nitric oxide, RhoA and alpha-smooth muscle actin expression in colon adenocarcinoma cells.

Colon carcinoma invasiveness is a process involving cell-cell and cell-matrix alterations, local proteolysis of the ECM (extracellular matrix) or changes in cytokine and growth factor levels.

In order to evaluate the role of TGF-beta1 (transforming growth factor-beta1) and small G protein RhoA in tumour progression, the influence of TGF-beta1 treatment or RhoA-associated kinase inhibitor on the production of NO (nitric oxide) and MMP-2 and MMP-9 (metalloproteinases-2 and -9) was analysed in three human colon adenocarcinoma cell lines (HT29, LS180, SW948) representing different stages of tumour development.

All the tested cell lines produced low amounts of MMP-2 and MMP-9. rhTGF-beta1 and the synthetic Rho kinase inhibitor (Y-27632) decreased MMP-2 secretion by colon cancer cells, especially in the most advanced stage of colon cancer. rhTGF-beta1 decreased NO secretion by cells, while Y-27632 had no effect on it.

Immunoblotting with anti-RhoA antibodies followed by densitometry revealed that RhoA levels were slightly increased after incubation of colon carcinoma cells (SW948) with rhTGF-beta1. rhTGF-beta1 induced alpha-smooth muscle actin (alpha-SMA) expression, especially in high Duke's grade of colon cancer, while Y-27632 blocked it.

Summing up, in colon carcinoma cells, TGF-beta1 and RhoA protein may regulate tumour invasiveness measured as MMP, NO and alpha-SMA expression or assayed using motility data and may be a good target for cancer therapy.

[MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Transforming Growth Factor beta1 / pharmacology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19947919.001).

[ISSN] 1095-8355

[Journal-full-title] Cell biology international

[ISO-abbreviation] Cell Biol. Int.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Actins; 0 / Amides; 0 / Pyridines; 0 / Recombinant Proteins; 0 / Transforming Growth Factor beta1; 138381-45-0 / Y 27632; 31C4KY9ESH / Nitric Oxide; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / rhoA GTP-Binding Protein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.

OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon.

MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection.

In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage.

Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.

CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Clin Oncol. 2004 Jun;27(3):304-6 [15170153.001]

[Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]

[Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34 [11829427.001]

[Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]

[Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]

[Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]

[Cites] Gut. 2006 Nov;55(11):1681 [17047131.001]

[Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]

[Cites] Eur J Surg Oncol. 2005 Feb;31(1):59-66 [15642427.001]

[Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]

[Cites] Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2 [18005779.001]

[Cites] Eur J Surg Oncol. 2008 Jul;34(7):771-5 [18079086.001]

[Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]

[Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]

[Cites] Ann Surg Oncol. 2008 Jun;15(6):1600-8 [18327530.001]

[Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]

[Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]

[Cites] Am Surg. 2004 Mar;70(3):235-40; discussion 240 [15055847.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]

[Cites] Cancer. 1967 Nov;20(11):1976-85 [6061631.001]

[Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]

(PMID = 19479270.001).

[ISSN] 1432-1262

[Journal-full-title] International journal of colorectal disease

[ISO-abbreviation] Int J Colorectal Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.

To investigate a possible contribution of post-translational changes to the progression of colon cancer and to overexpression of COX-2, we studied expression of HuR and COX-2 a cohort of colorectal adenocarcinomas and in colon cancer cell lines.

In tumor tissue of colon carcinomas we observed two different staining patterns of HuR: A nuclear expression in 98% as well as an additional cytoplasmic expression in 53% of cases.

Cytoplasmic expression of HuR was significantly associated with increased COX-2 expression as well as with high tumor stage.

In univariate Kaplan-Meier analysis, grading, tumor stage and nodal status but not HuR or COX-2 expression were prognostic factors for overall survival.

Our results suggest that the overexpression of HuR in colon cancer may be part of a regulatory pathway that controls the mRNA stability of cyclooxygenase-2 and provides an interesting example for a contribution of a dysregulation of mRNA stability to the progression of colorectal cancer.

[MeSH-major] Adenocarcinoma, Mucinous / metabolism. Antigens, Surface / metabolism. Colonic Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. Membrane Proteins / metabolism. RNA-Binding Proteins / metabolism

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Published online 23 June 2006.

(PMID = 16799479.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / Membrane Proteins; 0 / RNA-Binding Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.

BACKGROUND: Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions.

The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers.

METHODS: The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries.

RESULTS: Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.

Among stage-II patients, those receiving chemotherapy decreased from 57.6% in patients aged <or=50 years to 1.1% in those aged >or=85.

The corresponding percentages with stage III were 93.6% and 1.4%.

In multivariate analyses, other factors found to be independently and significantly associated with administration of adjuvant chemotherapy for stage II were extension of the cancer (stage IIA vs. stage IIB), clinical presentation (obstruction or perforation vs. uncomplicated cancer) and discussion of the case at a multidisciplinary case-review meeting.

For stage III, apart from age, discussion of the case at a multidisciplinary meeting was the only factor independently associated with administration of chemotherapy.

CONCLUSION: Adjuvant chemotherapy for stage-III colon cancer is used extensively for patients under 75 years of age.

On the other hand, a substantial percentage of stage-II colon cancer patients receive adjuvant chemotherapy despite its uncertain benefits.

[MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

(PMID = 20079591.001).

[ISSN] 0399-8320

[Journal-full-title] Gastroentérologie clinique et biologique

[ISO-abbreviation] Gastroenterol. Clin. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hyperplastic polyposis associated with two asynchronous colon cancers.

We report a patient with hyperplastic polyposis who had two asynchronous colon cancers, a combined adenoma-hyperplastic polyp, a serrated adenoma, and tubular adenomas.

Hyperplastic polyposis is thought to be a precancerous lesion; and adenocarcinoma arises from hyperplastic polyposis through the hyperplastic polyp-adenoma-carcinoma sequence.

In patients with multiple hyperplastic polyps, hyperplastic polyposis should be identified and followed up carefully in order to detect malignant transformation in the early stage.

[MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonic Neoplasms / pathology. Intestinal Polyps / pathology. Precancerous Conditions / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17589908.001).

[ISSN] 1007-9327

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] China

[Other-IDs] NLM/ PMC4436615

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease.

The expression of the genes coding TNFalpha and TNF RII receptors (TNF RII: TNFR2 membrane and soluble domain, TNFR2/R7 soluble domain) was analysed in colon cancer at the II and III stage of disease, by estimation of mRNA expression.

The study included 80 patients with histopathologically confirmed adenocarcinoma.

The highest number of mRNA TNF-alpha copies were investigated in all samples of tissue and independently of the stage of disease.

Simultaneously, we noticed the largest number of mRNA copies for TNFalpha and TNF R2/R7 in healthy cells at stage III of the disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18088549.001).

[ISSN] 0393-974X

[Journal-full-title] Journal of biological regulators and homeostatic agents

[ISO-abbreviation] J. Biol. Regul. Homeost. Agents

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer.

PURPOSE: The association hepatocyte growth factor receptor (Met) tyrosine kinase with prognosis and survival in colon cancer is unclear, due in part to the limitation of detection methods used.

EXPERIMENTAL DESIGN: Fluorescent-based IHC for Met was done in 583 colon cancer patients in a tissue microarray format.

RESULTS: In crossvalidated and univariate Cox analysis, the membrane relative to cytoplasm Met score was a significant predictor of survival in stage I (hazard ratio, 0.16; P = 0.006) and in stage II patients (hazard ratio, 0.34; P < or = 0.0005).

Met in the membrane alone was not a significant predictor of outcome in all patients or within stage.

CONCLUSIONS: These data indicate that the relative subcellular distribution of Met, as measured by novel automated image analysis, may be a valuable biomarker for estimating colon cancer prognosis.

[MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Cell Membrane / metabolism. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Cytoplasm / metabolism. Proto-Oncogene Proteins / metabolism. Receptors, Growth Factor / metabolism

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18559601.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Validation Studies

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Minimally invasive esophagectomy for stage I and II esophageal cancer.

The histologic type of cancer was squamous cell carcinoma in 109 (97.4%) patients and adenocarcinoma in 3 (2.6%).

Induction chemoradiotherapy, preoperative concomitant disease, and reconstruction using the colon did not increase morbidity.

For stage I disease, the 5-year survival rate of patients was 87.2%.

In stage II disease, it was 70.2%.

The survival of patients with stage I and II disease is satisfactory at the present time.

[MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagectomy / methods. Thoracic Surgery, Video-Assisted

Genetic Alliance. consumer health - Esophageal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16305846.001).

[ISSN] 1552-6259

[Journal-full-title] The Annals of thoracic surgery

[ISO-abbreviation] Ann. Thorac. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers.

PURPOSE: Locoregional recurrence is the most common complication after adenocarcinoma resection in the colon, despite adjuvant chemotherapy.

MATERIALS AND METHODS: Cell lines (IEC-6, SW-480 and SW-620) and colon polyps and normal adjacent tissues harvested from dimethylhydrazine (DMH) induced rats were used as in vitro and in vivo models of different metastatic stages of colon cancer.

RESULTS: SA was overexpressed on malignant colonic cells and tissues, and its expression correlated to the metastatic stage in vitro.

The binding of the cationic copolymers to the cell lines and tissues correlated with the charge density of the polymer and with the metastatic stage of the cell line.

Genetic Alliance. consumer health - Metastatic cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Pharm. 2003 Nov 28;267(1-2):1-12 [14602379.001]

[Cites] J Gastroenterol Hepatol. 2006 Mar;21(3):563-8 [16638099.001]

[Cites] FASEB J. 1997 Mar;11(4):248-55 [9068613.001]

[Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]

[Cites] Eur J Histochem. 1993;37(3):257-65 [7693064.001]

[Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36 [15722167.001]

[Cites] Cancer Res. 2002 Dec 1;62(23):6831-6 [12460895.001]

[Cites] Cancer Res. 1995 Apr 15;55(8):1675-9 [7712474.001]

[Cites] Nature. 2006 May 25;441(7092):451-6 [16724057.001]

[Cites] Gastrointest Endosc. 2004 May;59(6):634-41 [15114305.001]

[Cites] Cancer Cell Int. 2006 Jun 23;6:17 [16792817.001]

[Cites] Cancer. 1995 Sep 1;76(5):727-35 [8625173.001]

[Cites] Cancer Lett. 1993 Dec 20;75(3):143-9 [8313349.001]

[Cites] Annu Rev Biomed Eng. 1999;1:241-63 [11701489.001]

[Cites] J R Soc Med. 1983 Jun;76(6):467-72 [6864720.001]

[Cites] Cell Biol Int Rep. 1990 Mar;14(3):275-86 [2344628.001]

[Cites] J Neurooncol. 1986;4(1):23-9 [3746382.001]

[Cites] J Clin Invest. 1987 Nov;80(5):1245-54 [2890655.001]

[Cites] Biochemistry. 1979 Nov 27;18(24):5505-11 [92996.001]

[Cites] Surg Oncol Clin N Am. 2006 Jan;15(1):147-57 [16389155.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1482-7 [17244708.001]

[Cites] J Control Release. 2005 Aug 18;106(1-2):14-25 [16005094.001]

[Cites] Science. 1983 Aug 12;221(4611):673-5 [6603020.001]

[Cites] Acta Physiol Hung. 1994;82(1):3-13 [7976394.001]

[Cites] Rev Esp Fisiol. 1997 Dec;53(4):385-6 [9580472.001]

[Cites] J Histochem Cytochem. 2004 May;52(5):629-40 [15100240.001]

[Cites] Adv Drug Deliv Rev. 2004 Mar 3;56(4):459-80 [14969753.001]

[Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S189-99 [16113096.001]

[Cites] Mol Genet Metab. 1998 Jul;64(3):193-7 [9719628.001]

[Cites] Am J Surg. 2006 Nov;192(5):644-8 [17071200.001]

[Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):7-10 [16360005.001]

[Cites] Oncologist. 2006 Oct;11(9):973-80 [17030637.001]

[Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3056s-3058s [10541343.001]

(PMID = 17960470.001).

[ISSN] 0724-8741

[Journal-full-title] Pharmaceutical research

[ISO-abbreviation] Pharm. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Acrylamides; 0 / Wheat Germ Agglutinins; GZP2782OP0 / N-Acetylneuraminic Acid

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma.

On univariate survival analysis, patients with PTEN- adenocarcinoma revealed a poor overall and disease-free survival (P = 0.030 and P = 0.046, respectively).

On multivariate analysis, a significant difference was observed in patients with stage II cancer that was not observed in other stages.

CONCLUSIONS: Nuclear PTEN expression gradually decrease during the normal-adenoma-adenocarcinoma-metastasis sequence, which suggests an important role for PTEN in carcinogenesis.

Moreover, loss of nuclear PTEN expression was a marker of poor clinical outcome in patients with stage II colorectal cancer.

[MeSH-major] Adenocarcinoma / metabolism. Adenomatous Polyps / metabolism. Cell Nucleus / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. PTEN Phosphohydrolase / metabolism. Rectum / metabolism

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20102402.001).

[ISSN] 1365-2559

[Journal-full-title] Histopathology

[ISO-abbreviation] Histopathology

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.

Unlike some solid tumors, current evidence indicates that c-Met activation in colon cancer is unrelated to gene mutation, is ligand dependent, and occurs via a paracrine fashion.

METHODS: Primary tumor c-Met and HGF mRNA expression was analyzed in 60 colon adenocarcinomas.

CONCLUSION: Evaluation of the c-Met receptor in context of ligand, HGF, allows identification of a metastatic phenotype that correlates with advanced stage and poor survival. c-Met and HGF co-expression in the tumor microenvironment could be useful in the molecular staging of colon cancer and viable therapeutic targets.

[MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colonic Neoplasms / pathology. Hepatocyte Growth Factor / biosynthesis. Proto-Oncogene Proteins c-met / biosynthesis

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16945480.001).

[ISSN] 0304-3835

[Journal-full-title] Cancer letters

[ISO-abbreviation] Cancer Lett.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma.

MCRCs were significantly more common in the ascending colon than were ECRCs, but there was no significant dissimilarity to NECs.

Despite an infiltrative growth pattern, MCRC was less likely than ECRC to manifest with stage III or IV disease, but there was no stage-related difference from NECs.

[MeSH-major] Adenocarcinoma / pathology. Carcinoma, Medullary / pathology. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology

MedlinePlus Health Information. consumer health - Colorectal Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15762280.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Synchronous colon and gastric advanced carcinomas.

An unusual case of advanced synchronous colon and gastric carcinoma is described.

A 36 year old female was admitted to our Department with a stenosing right colon cancer diagnosed at endoscopy which was performed for lower crampy abdominal pain and gross blood in the stool.

Multiple colon polyps, distal to the tumor, were also detected.

On preoperative abdominal computed tomography, a stenosing right colon cancer, without evidence of abdominal diffusion, was confirmed.

At laparotomy, in addition to colon cancer, an antral gastric cancer was incidentally found.

At histology, a poorly differentiated gastric adenocarcinoma with signet ring-cell component (pT2, pN0; stage IB) and a moderately differentiated colon adenocarcinoma with a tubulovillous component (pT3, pN1; stage III, Stage Dukes C) were revealed.

MedlinePlus Health Information. consumer health - Stomach Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15943046.001).

[ISSN] 0392-9078

[Journal-full-title] Journal of experimental & clinical cancer research : CR

[ISO-abbreviation] J. Exp. Clin. Cancer Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.

BACKGROUND: The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX).

PATIENTS AND METHODS: This retrospective study included 233 unselected patients with stage III colon cancer treated by FL (n = 124) or FOLFOX (n = 109).

CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment of stage III colon cancer patients.

Hazardous Substances Data Bank. FLUOROURACIL .

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19833818.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.

PURPOSE: To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive colon cancer stage III for patients aged >or=75 yr and younger.

CONCLUSIONS: Adjuvant 5-FU chemotherapy should be considered for elderly patients aged >or=75 yr in good performance at high risk of recurrence of colon carcinoma after resection.

[MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]

[Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]

[Cites] Cancer Control. 1995 Mar;2(2 Suppl 1):36-38 [10887408.001]

[Cites] Pharmacol Rev. 2004 Jun;56(2):163-84 [15169926.001]

[Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]

[Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]

[Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]

[Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]

[Cites] Cancer. 2002 Apr 1;94(7):1931-8 [11932894.001]

[Cites] Lancet. 2000 May 6;355(9215):1588-96 [10821362.001]

[Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]

[Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]

[Cites] Ann Oncol. 2004 Apr;15(4):568-73 [15033660.001]

[Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]

[Cites] Am J Clin Oncol. 2003 Feb;26(1):103-6 [12576935.001]

[Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]

[Cites] Ann Oncol. 2005 May;16(5):767-72 [15817594.001]

[Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]

[Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]

[Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]

[Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]

[Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]

[Cites] J Clin Oncol. 1989 Oct;7(10):1447-56 [2778478.001]

[Cites] Am J Clin Oncol. 1982 Apr;5(2):227-36 [7091044.001]

[Cites] Ann Oncol. 2000 Aug;11(8):947-55 [11038030.001]

[Cites] J Clin Oncol. 1984 Jul;2(7):849-55 [6737023.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]

[Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]

[Cites] Cancer. 1995 Feb 1;75(3):775-81 [7828127.001]

[Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]

[Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]

[Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]

(PMID = 17303911.001).

[ISSN] 1357-0560

[Journal-full-title] Medical oncology (Northwood, London, England)

[ISO-abbreviation] Med. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil